540 related articles for article (PubMed ID: 28994348)
1. From pathogenesis to novel therapies in the treatment of primary biliary cholangitis.
Ronca V; Carbone M; Bernuzzi F; Malinverno F; Mousa HS; Gershwin ME; Invernizzi P
Expert Rev Clin Immunol; 2017 Dec; 13(12):1121-1131. PubMed ID: 28994348
[TBL] [Abstract][Full Text] [Related]
2. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
3. [Advances in the treatment of primary biliary cholangitis].
Li YM; Wang QX; Ma X
Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):805-809. PubMed ID: 29325272
[TBL] [Abstract][Full Text] [Related]
4. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
Wong LL; Hegade VS; Jones DEJ
Dig Dis; 2017; 35(4):359-366. PubMed ID: 28468009
[TBL] [Abstract][Full Text] [Related]
5. Investigational drugs in phase II clinical trials for primary biliary cholangitis.
Silveira MG; Lindor KD
Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457
[TBL] [Abstract][Full Text] [Related]
6. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
Bowlus CL; Kenney JT; Rice G; Navarro R
J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
[TBL] [Abstract][Full Text] [Related]
7. Primary biliary cholangitis: Old and novel therapy.
Floreani A; Mangini C
Eur J Intern Med; 2018 Jan; 47():1-5. PubMed ID: 28669591
[TBL] [Abstract][Full Text] [Related]
8. Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends.
Gao L; Wang L; Woo E; He X; Yang G; Bowlus C; Leung PSC; Gershwin ME
Clin Rev Allergy Immunol; 2020 Oct; 59(2):175-194. PubMed ID: 31713023
[TBL] [Abstract][Full Text] [Related]
9. Finding the cure for primary biliary cholangitis - Still waiting.
Tanaka A; Gershwin ME
Liver Int; 2017 Apr; 37(4):500-502. PubMed ID: 28371099
[TBL] [Abstract][Full Text] [Related]
10. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
Hirschfield GM; Dyson JK; Alexander GJM; Chapman MH; Collier J; Hübscher S; Patanwala I; Pereira SP; Thain C; Thorburn D; Tiniakos D; Walmsley M; Webster G; Jones DEJ
Gut; 2018 Sep; 67(9):1568-1594. PubMed ID: 29593060
[TBL] [Abstract][Full Text] [Related]
11. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
[TBL] [Abstract][Full Text] [Related]
12. Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
Parés A
Dig Dis; 2015; 33 Suppl 2():125-33. PubMed ID: 26642350
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?
Yang Y; He X; Rojas M; Leung PSC; Gao L
Front Immunol; 2023; 14():1184252. PubMed ID: 37325634
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.
Samur S; Klebanoff M; Banken R; Pratt DS; Chapman R; Ollendorf DA; Loos AM; Corey K; Hur C; Chhatwal J
Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472
[TBL] [Abstract][Full Text] [Related]
15. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
16. Advances in pharmacotherapy for primary biliary cirrhosis.
Mousa HS; Lleo A; Invernizzi P; Bowlus CL; Gershwin ME
Expert Opin Pharmacother; 2015 Apr; 16(5):633-43. PubMed ID: 25543678
[TBL] [Abstract][Full Text] [Related]
17. The challenges of primary biliary cholangitis: What is new and what needs to be done.
Terziroli Beretta-Piccoli B; Mieli-Vergani G; Vergani D; Vierling JM; Adams D; Alpini G; Banales JM; Beuers U; Björnsson E; Bowlus C; Carbone M; Chazouillères O; Dalekos G; De Gottardi A; Harada K; Hirschfield G; Invernizzi P; Jones D; Krawitt E; Lanzavecchia A; Lian ZX; Ma X; Manns M; Mavilio D; Quigley EM; Sallusto F; Shimoda S; Strazzabosco M; Swain M; Tanaka A; Trauner M; Tsuneyama K; Zigmond E; Gershwin ME
J Autoimmun; 2019 Dec; 105():102328. PubMed ID: 31548157
[TBL] [Abstract][Full Text] [Related]
18. Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review.
Suraweera D; Rahal H; Jimenez M; Viramontes M; Choi G; Saab S
Liver Int; 2017 Dec; 37(12):1877-1886. PubMed ID: 28517369
[TBL] [Abstract][Full Text] [Related]
19. Improving prognosis in primary biliary cholangitis - Therapeutic options and strategy.
Harms MH; van Buuren HR; van der Meer AJ
Best Pract Res Clin Gastroenterol; 2018; 34-35():85-94. PubMed ID: 30343714
[TBL] [Abstract][Full Text] [Related]
20. Primary biliary cholangitis: a comprehensive overview.
Lleo A; Marzorati S; Anaya JM; Gershwin ME
Hepatol Int; 2017 Nov; 11(6):485-499. PubMed ID: 29164395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
